Recently, the 2025 Science and Technology Innovation and Industrial Innovation Conference and the Golden Bull Sci-Tech Award Ceremony, organized by China Securities Journal, was officially held in Shanghai. Thanks to its outstanding technological innovation and strong market performance in the biopharmaceutical sector, AccuMedical stood out among numerous candidates and was honored with the 2025 Golden Bull Award for Sci-Tech Innovation Enterprise (Biopharmaceuticals).
This year’s Golden Bull Sci-Tech Awards focused on the theme of technological innovation, highlighting eight strategic emerging industries: next-generation information technology, artificial intelligence, aerospace, new energy, new materials, high-end equipment, biopharmaceuticals, and quantum technology. The awards recognize both listed and unlisted companies demonstrating excellence in these areas, promoting the healthy, sustainable, and high-quality development of China’s sci-tech innovation industry. As a signature financial brand created by China Securities Journal, the “Golden Bull Award” is one of the most influential honors in China’s capital market. The Sci-Tech Golden Bull Awards aim to foster new quality productive forces, guide resource allocation, accelerate the integration of technological and industrial innovation, and support the real economy—driving key advancements in China’s emerging high-tech industries. AccuMedical’s recognition with this award highlights its strong investment value in the biopharmaceutical segment.
Since its establishment, the company has upheld a commitment to technological innovation, dedicated to providing high-quality, cutting-edge medical devices in the field of neurointervention. Its newly upgraded Lattice NEXT, featuring a world-first “non-extended” tipless guidewire design, utilizes cobalt-chromium alloy, a proprietary mechanical balloon delivery system, and MIROR surface modification technology—filling multiple domestic technological gaps. These advancements enable smoother navigation and more controlled deployment, especially in challenging tortuous vessel cases during the treatment of intracranial aneurysms. Through breakthrough innovations, Lattice NEXT significantly reduces procedural complexity, shortens operation time, enhances patient outcomes, and improves surgical safety, representing a major leap forward in neurointerventional technology and addressing unmet clinical needs.
To date, AccuMedical has obtained NMPA approvals for 9 products, including Lattice and Lattice NEXT, and has filed 132 patent applications, with 73 patents granted. In 2023, the company was recognized as a National High-Tech Enterprise, and in 2024, it was selected as a National-level “Little Giant” Enterprise for its specialization and innovation.
Looking ahead, AccuMedical will continue to deepen its focus in the neurointervention field, guided by technological innovation. The company will further increase R&D investment, expand its product portfolio, and enhance product performance, striving to deliver superior products and services to patients and physicians worldwide. At the same time, AccuMedical will actively collaborate across industry, academia, research, and clinical practice to drive joint innovation, tackle core technological challenges in neurointervention, and elevate China’s medical device innovation capabilities and global competitiveness—contributing to the high-quality development of China’s neurointerventional medical device industry.